SCHEMBL979245

SCHEMBL979245

CCCCCCCCc1ccc(NS(=O)(=O)NC2(CC(=O)OCC)CCN(C)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT1 P31749 2/20 0.41
▸ IRS1 P35568 2/20 0.41
▸ GAB1 Q13480 2/20 0.41
▸ DRD2 P14416 3/20 0.39
▸ DRD3 P35462 3/20 0.39
▸ HTR2A P28223 2/20 0.39
▸ HTR2C P28335 2/20 0.39
▸ HTR6 P50406 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ SPHK1 Q9NYA1 5/20 0.38
▸ ACLY P53396 1/20 0.37
▸ MMP1 P03956 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15623158 0.88 DRD2 (0.44) DRD2DRD3HTR2AHTR2CHTR6
SCHEMBL981689 0.87 FAAH (0.38) DRD2DRD3HTR2AHTR2CHTR6
Iodide SCHEMBL982299 0.86 AKT1 (0.41) AKT1IRS1GAB1CA12CA1
SCHEMBL980157 0.85 AKT1 (0.43) AKT1IRS1GAB1DRD2DRD3
SCHEMBL979858 0.85 AKT1 (0.47) AKT1IRS1GAB1DRD2DRD3
Trifluoroacetic Acid SCHEMBL981686 0.83 S1PR1 (0.40) DRD2DRD3HTR2AHTR2CHTR6
SCHEMBL979229 0.83 S1PR1 (0.47) CA12CA1CA2CA9SPHK1
SCHEMBL977352 0.81 CA12 (0.37) DRD2DRD3HTR2AHTR2CHTR6
SCHEMBL979272 0.80 AKT1 (0.46) AKT1IRS1GAB1DRD2DRD3
SCHEMBL978582 0.79 S1PR1 (0.45) CA12CA1CA2CA9SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680282-B2 Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer UNIVERSITY HEALTH NETWORK (CA) 2014-03-25 — — US disclosed
US-20110015174-A1 CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2011-01-20 — — US disclosed
WO-2009015485-A1 CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-02-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015174-A1 CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER CPT1A, CPT1B, CPT2 AKT1 2154/4885IRS1 1546/4885GAB1 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback